{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T12:14:03Z","timestamp":1763468043470,"version":"3.38.0"},"reference-count":47,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2012,1,1]],"date-time":"2012-01-01T00:00:00Z","timestamp":1325376000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"name":"National Fund for Scientific Research"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"published-print":{"date-parts":[[2012,1]]},"DOI":"10.1016\/j.pnpbp.2011.08.007","type":"journal-article","created":{"date-parts":[[2011,8,18]],"date-time":"2011-08-18T03:35:17Z","timestamp":1313638517000},"page":"60-70","source":"Crossref","is-referenced-by-count":22,"title":["Increasing the density of the D2L receptor and manipulating the receptor environment are required to evidence the partial agonist properties of aripiprazole"],"prefix":"10.1016","volume":"36","author":[{"given":"Beryl","family":"Koener","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maryl\u00e8ne C.","family":"Focant","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Barbara","family":"Bosier","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean-Marie","family":"Maloteaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Emmanuel","family":"Hermans","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pnpbp.2011.08.007_bb0005","doi-asserted-by":"crossref","first-page":"1869","DOI":"10.1038\/sj.npp.1300940","article-title":"Antipsychotic-like vs cataleptogenic actions in mice of novel antipsychotics having D2 antagonist and 5-HT1A agonist properties","volume":"31","author":"Bardin","year":"2006","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0010","doi-asserted-by":"crossref","first-page":"438","DOI":"10.1016\/j.tips.2007.06.001","article-title":"Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance","volume":"28","author":"Bosier","year":"2007","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0015","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1124\/jpet.102.033175","article-title":"Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors","volume":"302","author":"Burris","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0020","doi-asserted-by":"crossref","first-page":"e2920","DOI":"10.1371\/journal.pone.0002920","article-title":"Study of a synthetic human olfactory receptor 17\u20134: expression and purification from an inducible mammalian cell line","volume":"3","author":"Cook","year":"2008","journal-title":"PLoS One"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0025","doi-asserted-by":"crossref","first-page":"28667","DOI":"10.1074\/jbc.M008644200","article-title":"Agonist regulation of D(2) dopamine receptor\/G protein interaction. Evidence for agonist selection of G protein subtype","volume":"276","author":"Cordeaux","year":"2001","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0030","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1126\/science.3854","article-title":"Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs","volume":"192","author":"Creese","year":"1976","journal-title":"Science"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0035","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.ejphar.2004.04.050","article-title":"Na+ modulation, inverse agonism, and anorectic potency of 4-phenylpiperidine opioid antagonists","volume":"494","author":"Emmerson","year":"2004","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0040","doi-asserted-by":"crossref","first-page":"1544","DOI":"10.1111\/j.1476-5381.1996.tb15572.x","article-title":"Pharmacological analysis of dopamine stimulation of [35S]-GTP gamma S binding via human D2short and D2long dopamine receptors expressed in recombinant cells","volume":"118","author":"Gardner","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0045","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1038\/sj.bjp.0702849","article-title":"Receptor density as a factor governing the efficacy of the dopamine D4 receptor ligands, L-745,870 and U-101958 at human recombinant D4.4 receptors expressed in CHO cells","volume":"128","author":"Gazi","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0050","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/S0014-2999(99)00569-5","article-title":"Enhanced striatal dopamine D(2) receptor-induced [35S] GTPgammaS binding after haloperidol treatment","volume":"382","author":"Geurts","year":"1999","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0055","doi-asserted-by":"crossref","first-page":"7354","DOI":"10.1074\/jbc.270.13.7354","article-title":"Alternative splicing of the dopamine D2 receptor directs specificity of coupling to G-proteins","volume":"270","author":"Guiramand","year":"1995","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0060","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/S0163-7258(03)00051-2","article-title":"Biochemical and pharmacological control of the multiplicity of coupling at G-protein-coupled receptors","volume":"99","author":"Hermans","year":"2003","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0065","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1038\/sj.bjp.0702359","article-title":"Effects of varying the expression level of recombinant human mGlu1alpha receptors on the pharmacological properties of agonists and antagonists","volume":"126","author":"Hermans","year":"1999","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0070","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/S0014-2999(01)00775-0","article-title":"Pharmacological characterisation of human 5-HT2 receptor subtypes","volume":"414","author":"Jerman","year":"2001","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0075","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.pnpbp.2006.09.007","article-title":"Dopamine D2 receptor partial agonists display differential or contrasting characteristics in membrane and cell-based assays of dopamine D2 receptor signaling","volume":"31","author":"Jordan","year":"2007","journal-title":"Prog Neuropsychopharmacol Biol Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0080","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1176\/appi.ajp.158.3.360","article-title":"Does fast dissociation from the dopamine D(2) receptor explain the action of atypical antipsychotics?: a new hypothesis","volume":"158","author":"Kapur","year":"2001","journal-title":"Am J Psychiatry"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0085","doi-asserted-by":"crossref","first-page":"456","DOI":"10.1016\/S0165-6147(97)01136-X","article-title":"Differences between natural and recombinant G protein-coupled receptor systems with varying receptor\/G protein stoichiometry","volume":"18","author":"Kenakin","year":"1997","journal-title":"Trends Pharmacol Sci"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0090","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/S0022-3565(25)10600-9","article-title":"7-(4-[4-(2,3-Dichlorophenyl)-1-piperazinyl] butyloxy)-3,4-dihydro-2(1H)-quinolinone (OPC-14597), a new putative antipsychotic drug with both presynaptic dopamine autoreceptor agonistic activity and postsynaptic D2 receptor antagonistic activity","volume":"274","author":"Kikuchi","year":"1995","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0095","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1124\/jpet.301.3.1179","article-title":"Functional selectivity of dopamine receptor agonists. II. Actions of dihydrexidine in D2L receptor-transfected MN9D cells and pituitary lactotrophs","volume":"301","author":"Kilts","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0100","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1124\/jpet.109.160432","article-title":"Cariprazine (RGH-188), a dopamine D(3) receptor-preferring, D(3)\/D(2) dopamine receptor antagonist-partial agonist antipsychotic candidate: in vitro and neurochemical profile","volume":"333","author":"Kiss","year":"2010","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0105","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1007\/s00210-010-0577-7","article-title":"Pharmacological blockade of dopamine D receptors by aripiprazole is not associated with striatal sensitization","volume":"383","author":"Koener","year":"2011","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0110","doi-asserted-by":"crossref","first-page":"1349","DOI":"10.1124\/mol.106.032722","article-title":"Protean agonism at the dopamine D2 receptor: (S)-3-(3-hydroxyphenyl)-N-propylpiperidine is an agonist for activation of Go1 but an antagonist\/inverse agonist for Gi1, Gi2, and Gi3","volume":"71","author":"Lane","year":"2007","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0115","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1124\/jpet.107.134296","article-title":"G protein coupling and ligand selectivity of the D2L and D3 dopamine receptors","volume":"325","author":"Lane","year":"2008","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0120","doi-asserted-by":"crossref","first-page":"612","DOI":"10.1016\/S0893-133X(98)00099-2","article-title":"Interactions of the novel antipsychotic aripiprazole (OPC-14597) with dopamine and serotonin receptor subtypes","volume":"20","author":"Lawler","year":"1999","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0125","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1038\/sj.bjp.0706866","article-title":"Assays for enhanced activity of low efficacy partial agonists at the D(2) dopamine receptor","volume":"149","author":"Lin","year":"2006","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0130","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/0014-2999(86)90675-8","article-title":"Receptor reserve at striatal dopamine autoreceptors: implications for selectivity of dopamine agonists","volume":"123","author":"Meller","year":"1986","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0135","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0014-2999(96)00350-0","article-title":"Inhibition by a putative antipsychotic quinolinone derivative (OPC-14597) of dopaminergic neurons in the ventral tegmental area","volume":"310","author":"Momiyama","year":"1996","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0140","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1124\/jpet.301.3.1166","article-title":"Functional selectivity of dopamine receptor agonists. I. Selective activation of postsynaptic dopamine D2 receptors linked to adenylate cyclase","volume":"301","author":"Mottola","year":"2002","journal-title":"J Pharmacol Exp Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0145","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/S0026-895X(25)11023-7","article-title":"Regulation of dopamine D2 receptors by sodium and pH","volume":"39","author":"Neve","year":"1991","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0150","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1124\/mol.60.2.373","article-title":"Modeling and mutational analysis of a putative sodium-binding pocket on the dopamine D2 receptor","volume":"60","author":"Neve","year":"2001","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0155","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1016\/S0006-2952(03)00040-6","article-title":"Interaction of the D2short dopamine receptor with G proteins: analysis of receptor\/G protein selectivity","volume":"65","author":"Nickolls","year":"2003","journal-title":"Biochem Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0160","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1016\/j.neuropharm.2004.06.010","article-title":"The influence of G protein subtype on agonist action at D2 dopamine receptors","volume":"47","author":"Nickolls","year":"2004","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0165","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/S0167-4889(98)00118-9","article-title":"Modulation of agonist binding to recombinant human alpha2-adrenoceptors by sodium ions","volume":"1448","author":"Pihlavisto","year":"1998","journal-title":"Biochim Biophys Acta"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0170","doi-asserted-by":"crossref","first-page":"13413","DOI":"10.1073\/pnas.212519199","article-title":"Structure and function in rhodopsin: a tetracycline-inducible system in stable mammalian cell lines for high-level expression of opsin mutants","volume":"99","author":"Reeves","year":"2002","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0175","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.neulet.2010.01.065","article-title":"Modulation of histamine H(3) receptor function by monovalent ions","volume":"472","author":"Schnell","year":"2010","journal-title":"Neurosci Lett"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0180","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1111\/j.1755-5949.2010.00162.x","article-title":"All roads to schizophrenia lead to dopamine supersensitivity and elevated dopamine D2 (high) receptors","volume":"17","author":"Seeman","year":"2011","journal-title":"CNS Neurosci Ther"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0185","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1038\/261717a0","article-title":"Antipsychotic drug doses and neuroleptic\/dopamine receptors","volume":"261","author":"Seeman","year":"1976","journal-title":"Nature"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0190","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1000884","article-title":"Induced effects of sodium ions on dopaminergic G-protein coupled receptors","volume":"6","author":"Selent","year":"2010","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0195","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1038\/sj.bjp.0703382","article-title":"Effects of sodium on agonist efficacy for G-protein activation in mu-opioid receptor-transfected CHO cells and rat thalamus","volume":"130","author":"Selley","year":"2000","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0200","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/0028-3908(95)00059-F","article-title":"Behavioural and neurochemical effects of OPC-14597, a novel antipsychotic drug, on dopaminergic mechanisms in rat brain","volume":"34","author":"Semba","year":"1995","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0205","doi-asserted-by":"crossref","first-page":"1400","DOI":"10.1038\/sj.npp.1300203","article-title":"Aripiprazole, a novel atypical antipsychotic drug with a unique and robust pharmacology","volume":"28","author":"Shapiro","year":"2003","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0210","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1016\/j.ejphar.2005.02.051","article-title":"Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic","volume":"515","author":"Tadori","year":"2005","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0215","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.ejphar.2009.02.007","article-title":"Receptor reserve-dependent properties of antipsychotics at human dopamine D2 receptors","volume":"607","author":"Tadori","year":"2009","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0220","doi-asserted-by":"crossref","first-page":"141","DOI":"10.2174\/1568007024606195","article-title":"Partial dopamine agonists and dopaminergic stabilizers, in the treatment of psychosis","volume":"1","author":"Tamminga","year":"2002","journal-title":"Curr Drug Targets CNS Neurol Disord"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0225","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/sj.npp.1301071","article-title":"Aripiprazole has functionally selective actions at dopamine D2 receptor-mediated signaling pathways","volume":"32","author":"Urban","year":"2007","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0230","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1002\/syn.890210211","article-title":"Spare receptors and intrinsic activity: studies with D1 dopamine receptor agonists","volume":"21","author":"Watts","year":"1995","journal-title":"Synapse"},{"key":"10.1016\/j.pnpbp.2011.08.007_bb0235","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1016\/0014-2999(88)90523-7","article-title":"Receptor reserve at striatal dopamine receptors modulating the release of [3H] dopamine","volume":"155","author":"Yokoo","year":"1988","journal-title":"Eur J Pharmacol"}],"container-title":["Progress in Neuro-Psychopharmacology and Biological Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611002545?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0278584611002545?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,8]],"date-time":"2025-03-08T22:13:44Z","timestamp":1741472024000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0278584611002545"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,1]]},"references-count":47,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2012,1]]}},"alternative-id":["S0278584611002545"],"URL":"https:\/\/doi.org\/10.1016\/j.pnpbp.2011.08.007","relation":{},"ISSN":["0278-5846"],"issn-type":[{"type":"print","value":"0278-5846"}],"subject":[],"published":{"date-parts":[[2012,1]]}}}